Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas. This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.